Alison B. Hickman

Alison B. Hickman

Auto-generated profile, based on publicly available information

Alison B. Hickman

Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Molecular Cell
Verified
Journal Article
Closed access
DKDalibor Kosek
Dalibor Kosek
IGIvana Grabundzija
Ivana Grabundzija
HLHaotian Lei
Haotian Lei
IBIlija Bilic
Ilija Bilic
HWHuaibin Wang
Huaibin Wang
FDFred Dyda
Fred Dyda

8 January 2020 in eLife
Verified
Journal Article
Open access
AHAlison B Hickman
Alison B Hickman
SKShweta Kailasan
Shweta Kailasan
PGPavol Genzor
Pavol Genzor
AHAstrid D Haase
Astrid D Haase
FDFred Dyda
Fred Dyda
Key to CRISPR-Cas adaptive immunity is maintaining an ongoing record of invading nucleic acids, a process carried out by the Cas1-Cas2 complex that integrates short segments of foreign genetic material (spacers) into the CRISPR locus. It is hypothesized that Cas1 evolved from casposases, a novel class of transposases. We show here that the Methanosarcina mazei casposase can integrate varied forms of the casposon end in vitro, and recapitulates several properties of CRISPR-Cas integrases including site-specificity. The X-ray structure of the casposase bound to DNA representing the product of integration reveals a tetramer with target DNA bound snugly between two dimers in which single-stranded casposon end binding resembles that of spacer 3'-overhangs. The differences between transposase and CRISPR-Cas integrase are largely architectural, and it appears that evolutionary change involved changes in protein-protein interactions to favor Cas2 binding over tetramerization; this in turn led to preferred integration of single spacers over two transposon ends.

20 September 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
AHAlison B Hickman
Alison B Hickman
AVAndrea Regier Voth
Andrea Regier Voth
HEHosam Ewis
Hosam Ewis
XLXianghong Li
Xianghong Li
NCNancy L Craig
Nancy L Craig
FDFred Dyda
Fred Dyda
Some DNA transposons relocate from one genomic location to another using a mechanism that involves generating double-strand breaks at their transposon ends by forming hairpins on flanking DNA. The same double-strand break mode is employed by the V(D)J recombinase at signal-end/coding-end junctions during the generation of antibody diversity. How flanking hairpins are formed during DNA transposition has remained elusive. Here, we describe several co-crystal structures of the Hermes transposase bound to DNA that mimics the reaction step immediately prior to hairpin formation. Our results reveal a large DNA conformational change between the initial cleavage step and subsequent hairpin formation that changes which strand is acted upon by a single active site. We observed that two factors affect the conformational change: the complement of divalent metal ions bound by the catalytically essential DDE residues, and the identity of the –2 flanking base pair. Our data also provides a mechanistic link between the efficiency of hairpin formation (an A:T basepair is favored at the –2 position) and Hermes' strong target site preference. Furthermore, we have established that the histidine residue within a conserved C/DxxH motif present in many transposase families interacts directly with the scissile phosphate, suggesting a crucial role in catalysis.

9 December 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
WLWentian Luo
Wentian Luo
AHAlison B Hickman
Alison B Hickman
PGPavol Genzor
Pavol Genzor
RGRodolfo Ghirlando
Rodolfo Ghirlando
CFChristopher M Furman
Christopher M Furman
MWMatthew H Wilson
Matthew H Wilson
DNA transposon systems are widely used in mammalian cells for genetic modification experiments, but their regulation remains poorly understood. We used biochemical and cell-based assays together with AlphaFold modeling and rational protein redesign to evaluate aspects of piggyBac transposition including the previously unexplained role of the transposase N-terminus and the need for asymmetric transposon ends for cellular activity. We found that phosphorylation at predicted casein kinase II sites in the transposase N-terminus inhibits transposition, most likely by preventing transposase–DNA interactions. Deletion of the region containing these sites releases inhibition thereby enhancing activity. We also found that the N-terminal domain promotes transposase dimerization in the absence of transposon DNA. When the N-terminus is deleted, the transposase gains the ability to carry out transposition using symmetric transposon left ends. This novel activity is also conferred by appending a second C-terminal domain. When combined, these modifications together result in a transposase that is highly active when symmetric transposon ends are used. Our results demonstrate that transposase N-terminal phosphorylation and the requirement for asymmetric transposon ends both negatively regulate piggyBac transposition in mammalian cells. These novel insights into the mechanism and structure of the piggyBac transposase expand its potential use for genomic applications.

16 January 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
Susu HESusu HE
Susu HE
NTNoor M. Taher
Noor M. Taher
KHKelli L. Hvorecny
Kelli L. Hvorecny
MRMichael J. Ragusa
Michael J. Ragusa
CBChristopher D. Bahl
Christopher D. Bahl
DMDean R. Madden
Dean R. Madden
The opportunistic pathogen Pseudomonas aeruginosa infects cystic fibrosis (CF) patient airways and produces a virulence factor Cif that is associated with worse outcomes. Cif is an epoxide hydrolase that reduces cell-surface abundance of the cystic fibrosis transmembrane conductance regulator (CFTR) and sabotages pro-resolving signals. Its expression is regulated by a divergently transcribed TetR family transcriptional repressor. CifR represents the first reported epoxide-sensing bacterial transcriptional regulator, but neither its interaction with cognate operator sequences nor the mechanism of activation has been investigated. Using biochemical and structural approaches, we uncovered the molecular mechanisms controlling this complex virulence operon. We present here the first molecular structures of CifR alone and in complex with operator DNA, resolved in a single crystal lattice. Significant conformational changes between these two structures suggest how CifR regulates the expression of the virulence gene cif . Interactions between the N-terminal extension of CifR with the DNA minor groove of the operator play a significant role in the operator recognition of CifR. We also determined that cysteine residue Cys107 is critical for epoxide sensing and DNA release. These results offer new insights into the stereochemical regulation of an epoxide-based virulence circuit in a critically important clinical pathogen.

16 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRaju Mandal
Raju Mandal
AHAlison B. Hickman
Alison B. Hickman
RDRhea P. Desai
Rhea P. Desai
APAlexandria Primich
Alexandria Primich
FDFred Dyda
Fred Dyda
Summary: Eukaryotic DNA transpososomes assemble as nucleoprotein complexes containing multiple identical transposase protomers. We determined the structure of the hyperactive Myotis lucifugus piggyBat transpososome and discovered that it uses an unusual crescent-shaped, asymmetric tetramer to synapse divergent inverted terminal repeats. We found that identical amino-acid sequence motifs adopt distinct roles to mediate two modes of DNA binding: one to perform strand transfer and one, devoid of catalytic activity, that promotes synapsis while simultaneously protecting the transposon from auto-destructive internal cleavage by its active sites. Guided by the observed modularity of the assembly, we engineered an obligate heterodimeric system by identifying mutations that suppress homodimer formation and paired this with specific point mutations that prevent non-targeted integration. By adding to the heterodimer two different TALE domains designed to bind a human genomic safe harbor sequence, we achieved >98% targeted integration at the intended sequence in a plasmid-based assay, validating the viability of heterodimeric transposases for genomic applications.